|Bid||470.51 x 800|
|Ask||481.89 x 900|
|Day's Range||473.49 - 483.71|
|52 Week Range||250.21 - 485.00|
|Beta (5Y Monthly)||0.99|
|PE Ratio (TTM)||39.38|
|Forward Dividend & Yield||0.88 (0.18%)|
|Ex-Dividend Date||Sep 14, 2020|
|1y Target Est||N/A|
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2020.
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced it has received an expansion of its Emergency Use Authorization (EUA) for the TaqPath COVID-19 Combo Kit to include an additional sample collection method provided by Everlywell, a leading digital health testing company. The TaqPath test is authorized for use with the Everlywell COVID-19 Test Home Collection Kit, which enables individuals to self-collect nasal swab specimens when determined by a healthcare provider to be appropriate based on results of a COVID-19 questionnaire.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced plans to develop two new sterile filling lines in Singapore to extend capacity to the Asia-Pacific region for the development and manufacture of therapies and vaccines.